Sarepta Therapeutics, Inc. (SRPT) income statement
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3086% below fair value
$14.53−0.24 (-1.62%)
Close on Nov 18, 2026Market cap $1.53BP/E –Yield –
Sarepta Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 110.0%
- Operating margin
- -7.3%
- Net margin
- -6.9%
- Return on equity, FY2025
- -53.5%
Financial strength
- Current ratio
- 4.42
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 113.6%
Valuation
- P/E ratio
- –
- Price to sales
- 0.78
- Price to book
- 1.00
- Dividend yield
- –
See a number that looks wrong?